Sargramostim in acute radiation syndrome.
Hillard M LazarusJohn McManusRobert Peter GalePublished in: Expert opinion on biological therapy (2022)
ratio suggests giving sargramostim soon after exposure and is favored over HCT based on greater safety and fewer resource requirements, especially in the context of large-scale exposures which might occur after use of a tactical nuclear weapon or nuclear terrorism.